精神分裂症症状严重度预测维思通的6周疗效  

Predicted the effects of risperidone treatment at 6 week in patients with schizophrenia via the severity of pretreatment symptoms

作　　者：喻东山[1] 徐捷[1] 孙旦晖[1] 曾彦英[1] 高小宁[1] 蒋晓军[1] 

机构地区：[1]南京医科大学附属脑科医院,210029

出　　处：《神经疾病与精神卫生》2007年第2期111-112,115,共3页Journal of Neuroscience and Mental Health

基　　金：江苏省教育厅指导性课题(01KJD320023)

摘　　要：目的通过精神分裂症疗前症状的严重度预测维思通治疗6周时的疗效。方法对27例服用维思通(3.9±1.0)mg/d的精神分裂症患者在治疗前和治疗6周末分别评定简明精神病量表(BPRS)。结果疗前BPRS总分与6周BPRS总分减分值相关(r=0.526,P<0.05)。同样,焦虑忧郁、缺乏活力、思维障碍、激活性和敌对猜疑因子的疗前分分别与6周减分值有正相关(r分别为0.965、0.525,0.604、0.715和0.882,P<0.05)。结论疗前总症状或各症状群越重,维思通治疗6周后的相关症状改善越明显,基线各因子的预测效率以焦虑忧郁和敌对猜疑为最高,激活性为中度,而思维障碍和缺乏活力为低度。Objective To predict the effects of risperidone treatment at 6 weeks by the severity of pretreatment symptoms in patients with schizophrenia. Methods It was estimated for Brief Psychiatric Rating Scale （BPRS） in 27 patients with schizophrenia taking risperidone （3. 9± 1.0） at pretreatment and post treatment 6 weeks, respectively. Results There was a significant correlation between pretreatment total score of BPRS and post treatment minus score of BPRS at 6 weeks （r=0. 526, P 〈0. 05）. There was a significant correlation between pretreatment score and post treatment score at 6 weeks for anxiety--depression factor, anergia factor, thought disturbance factor, activitation factor and hostile-suspiciousness factor, respectively （r=0. 965, 0. 525, 0. 604, 0. 715 and 0. 882, respectively, P 〈0. 05）. Conclusions More severity of total symptom and syndromes, more improvement of total symptoms and syndromes when risperidone treated for 6 weeks, respectively. Predicted efficiency of baseline factors was higher for anxiety--depression factor and hostile--suspiciousness factor, was modest for activitation factor and was lower for thought disturbance factor and anergia factor.

关 键 词：精神分裂症 维思通 疗效 预测 

分 类 号：R749.3[医药卫生—神经病学与精神病学]